Leukocytoclastic Vasculitis with Systemic Organ Involvement When First-Line Immunosuppression Has Not Achieved Disease Remission

This protocol applies to patients with leukocytoclastic vasculitis (LCV) with systemic organ involvement — including ANCA-associated vasculitis, cryoglobulinemic vasculitis, IgA vasculitis, hypocomplementemic urticarial vasculitis, or connective tissue disease — in whom initial immunosuppressive therapy has not achieved disease remission.

Clinical Scenario

LCV with systemic organ involvement encompasses several underlying diagnoses: ANCA-associated vasculitis, cryoglobulinemic vasculitis, IgA vasculitis, hypocomplementemic urticarial vasculitis, and connective tissue disease. When a systemic vasculitis is the cause of LCV, the severity of organ involvement and the specific associated disease together determine the intensity of treatment required.

Why Escalation Is Indicated

First-line therapy for LCV with systemic involvement — azathioprine, methotrexate, or mycophenolate mofetil — has not achieved the primary goal of disease remission. This protocol describes the approach taken at that point of escalation.

Next-Line Approach (Partial Overview)

In patients with organ-threatening systemic LCV refractory to first-line agents, stronger immunosuppressive therapy or targeted biologic approaches may be considered. The complete structured protocol — covering the full algorithm, agent selection criteria, and sequencing — is available below.

Treatment Goal

Disease remission.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/rheumatology/keac115

Conversely, when a systemic vasculitis is the cause of LCV, higher doses of corticosteroids or immunosuppressive agents are required, according to the severity of organ involvement and the underlying associated disease.
Stronger and more toxic agents, such as cyclophosphamide may be effective, but should be limited to severe systemic vasculitides with organ-threatening involvement.
Finally, in the current era of biologic therapies, targeting anti-CD20 with rituximab has now an established role in the treatment of ANCA-associated vasculitides, as well as in cryoglobulinemic vasculitis and HUV.
Rituximab appears promising also for HSP, when severe systemic or renal involvement favors an immunosuppressive or a corticosteroids sparing therapy.
When polyneuropathy or kidney involvement are present, immunosuppressive treatment or plasma-exchange strategies are usually required.
In general, the treatment depends on the diagnosis and aims to induce and maintain disease remission.

View source ↗